My early work with outstanding mentors, who were pediatric rheumatologists, led me to pursue my clinical and research interests. During my fellowship, the unfortunate death of a patient from macrophage activation syndrome (MAS) prompted me to further study this life-threatening complication of systemic juvenile idiopathic arthritis.

Currently, I focus on identifying risk factors and new therapeutic targets in MAS. Our transnational studies have identified interferon gamma (INF), a dimerized soluble cytokine, as a therapeutic target in patients suffering from MAS. This discovery provided the rationale for a new clinical trial that is currently underway.

My research is funded by the National Institutes of Health (NIH) and the Systemic Juvenile Idiopathic Arthritis (SJIA) Foundation. I have also received research grants from Sobi, Novartis and AB2Bio.

MD: Leningrad (St. Petersburg) Pediatric Medical Institute, Russia, 1986.

Residency: Leningrad (St. Petersburg) Medical Institute, Russia, 1988; Children's Hospital Medical Center, Cincinnati, OH, 1998.

Fellowship: Leningrad (St. Petersburg) Pediatric Medical Institute, Russia, 1991; Children's Hospital Medical Center, Cincinnati, OH, 1995.

Certification: Pediatrics, 1999.

Services and Specialties

Rheumatology, Lupus, Rare Lung Diseases

Research Areas


Additional Languages

French, Russian

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information


OP0166 LONG-TERM FOLLOW-UP OF PATIENTS ADMINISTERED EMAPALUMAB, AN ANTI–INTERFERON-Γ MONOCLONAL ANTIBODY, TO TREAT MACROPHAGE ACTIVATION SYNDROME (MAS) SECONDARY TO SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). De Benedetti, F; Grom, A; Brogan, P; Bracaglia, C; Pardeo, M; Marucci, G; Eleftheriou, D; Papadopoulou, C; Schulert, G; Quartier, P; et al. Annals of the Rheumatic Diseases. 2023; 82:110-111.

Efficacy and safety of emapalumab in macrophage activation syndrome. De Benedetti, F; Grom, AA; Brogan, PA; Bracaglia, C; Pardeo, M; Marucci, G; Eleftheriou, D; Papadopoulou, C; Schulert, GS; Quartier, P; et al. Annals of the Rheumatic Diseases. 2023; 82:857-865.

Lung Ultrasound in Children With Systemic Juvenile Idiopathic Arthritis-Associated Interstitial Lung Disease. Vega-Fernandez, P; Ting, TV; Mar, DA; Schapiro, AH; Deluna, MD; Saper, VE; Grom, AA; Schulert, GS; Fairchild, RM. Arthritis Care and Research. 2023; 75:983-988.

Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis. Miraldi Utz, V; Angeles-Han, ST; Mwase, N; Cassedy, A; Hennard, T; Lovell, DJ; Lopper, S; Brunner, HI; Dosunmu, EO; Grom, AA; et al. American Journal of Ophthalmology. 2022; 244:183-195.

Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. Chen, G; Deutsch, GH; Schulert, GS; Zheng, H; Jang, SR; Trapnell, B; Lee, PY; Macaubas, C; Ho, K; Schneider, C; et al. Arthritis and Rheumatology. 2022; 74:1271-1283.

International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Chalhoub, NE; Wenderfer, SE; Levy, DM; Rouster-Stevens, K; Aggarwal, A; Savani, SI; Ruth, NM; Arkachaisri, T; Qiu, T; Merritt, A; et al. Arthritis and Rheumatology. 2022; 74:263-273.

S100 proteins, cytokines, and chemokines as tear biomarkers in children with juvenile idiopathic arthritis-associated uveitis. Angeles-Han, ST; Miraldi Utz, V; Thornton, S; Schulert, G; Rodriguez-Smith, J; Kauffman, A; Sproles, A; Mwase, N; Hennard, T; Grom, A; et al. Ocular Immunology and Inflammation (Informa). 2021; 29:1616-1620.

IFN-γ is essential for alveolar macrophage-driven pulmonary inflammation in macrophage activation syndrome. Gao, DK; Salomonis, N; Henderlight, M; Woods, C; Thakkar, K; Grom, AA; Thornton, S; Jordan, MB; Wikenheiser-Brokamp, KA; Schulert, GS. JCI insight. 2021; 6:e147593.

Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study. Rodriguez-Smith, JJ; Verweyen, EL; Clay, GM; Esteban, YM; de Loizaga, SR; Baker, EJ; Do, T; Dhakal, S; Lang, SM; Grom, AA; et al. The Lancet. Rheumatology. 2021; 3:e574-e584.

Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis. Verweyen, EL; Pickering, A; Grom, AA; Schulert, GS. Arthritis and Rheumatology. 2021; 73:1334-1340.

From the Blog

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

Overall Patient Rating